Next generation antibody therapeutics
Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.
The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
Crescendo brings together two technologies invented by scientists at the Babraham Institute in Cambridge: a novel transgenic technology for in vivo generation of human heavy chain antibodies (and thereby VH fragments), and a ribosome display platform for affinity optimisation in vitro. These are being developed to generate a combined platform for discovery and optimisation of human VH-based therapeutics that addressess key issues with existing in vitro or non-human in vivo platforms.
